Truist Financial Corp increased its stake in Genmab A/S (NASDAQ:GMAB – Get Rating) by 37.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 20,578 shares of the company’s stock after buying an additional 5,568 shares during the period. Truist Financial Corp’s holdings in Genmab A/S were worth $662,000 as of its most recent filing with the SEC.
Other hedge funds have also recently made changes to their positions in the company. International Biotechnology Trust PLC purchased a new position in Genmab A/S in the 2nd quarter worth approximately $57,000. Private Capital Group LLC lifted its position in Genmab A/S by 14.1% during the second quarter. Private Capital Group LLC now owns 2,677 shares of the company’s stock valued at $87,000 after purchasing an additional 331 shares during the period. Captrust Financial Advisors lifted its holdings in shares of Genmab A/S by 62.0% during the 1st quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock valued at $96,000 after buying an additional 1,017 shares during the period. Wipfli Financial Advisors LLC bought a new stake in Genmab A/S during the third quarter valued at approximately $171,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Genmab A/S by 12.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 8,988 shares of the company’s stock valued at $292,000 after buying an additional 1,019 shares in the last quarter. 6.73% of the stock is currently owned by institutional investors.
Genmab A/S Trading Up 2.3 %
NASDAQ GMAB opened at $40.39 on Friday. The company has a 50-day moving average price of $43.35 and a two-hundred day moving average price of $38.58. The stock has a market cap of $26.64 billion, a price-to-earnings ratio of 33.11, a price-to-earnings-growth ratio of 1.18 and a beta of 1.02. Genmab A/S has a 52 week low of $26.19 and a 52 week high of $47.50.
Analyst Ratings Changes
A number of research firms recently issued reports on GMAB. SVB Leerink upped their price target on shares of Genmab A/S to $33.00 and gave the company a “market perform” rating in a research note on Thursday, November 10th. Citigroup downgraded shares of Genmab A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 20th. AlphaValue raised Genmab A/S to a “reduce” rating in a research report on Thursday, November 17th. DNB Markets downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Monday, October 17th. Finally, JPMorgan Chase & Co. raised their price target on shares of Genmab A/S from 3,450.00 to 3,600.00 and gave the company an “overweight” rating in a research note on Tuesday, January 3rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $632.12.
Genmab A/S Company Profile
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.